Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye

Darrell E White,1 Yang Zhao,2 Abayomi Ogundele,2 Nicole Fulcher,3 Annabel Acs,3 Laura Moore-Schiltz,3 Paul M Karpecki4 1Department of Ophthalmology, SkyVision Centers, Westlake, OH 44145, USA; 2Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Princeton, NJ 08540, USA; 3Outcomes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	White DE, Zhao Y, Ogundele A, Fulcher N, Acs A, Moore-Schiltz L, Karpecki PM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	dry eye disease adherence persistence cyclosporine ophthalmic emulsion lifitegrast ophthalmic solution Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0e24e77112774847966722de87e731be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0e24e77112774847966722de87e731be
record_format	dspace
spelling	oai:doaj.org-article:0e24e77112774847966722de87e731be2021-12-02T03:19:31ZReal-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye1177-5483https://doaj.org/article/0e24e77112774847966722de87e731be2019-11-01T00:00:00Zhttps://www.dovepress.com/real-world-treatment-patterns-of-cyclosporine-ophthalmic-emulsion-and--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Darrell E White,1 Yang Zhao,2 Abayomi Ogundele,2 Nicole Fulcher,3 Annabel Acs,3 Laura Moore-Schiltz,3 Paul M Karpecki4 1Department of Ophthalmology, SkyVision Centers, Westlake, OH 44145, USA; 2Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Princeton, NJ 08540, USA; 3Outcomes Research, IBM Watson Health, Cambridge, MA 02142, USA; 4Corneal Services and Advanced OSD Clinic, University of Pikeville Kentucky College of Optometry, Pikeville, KY 41501, USACorrespondence: Yang ZhaoHealth Economics and Outcomes Research, Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540, USATel +1 609 720 8132Email yang.zhao@sunpharma.comPurpose: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED).Design: Retrospective insurance claims study.Methods: Adult patients with DED and ≥1 prescription claim for CYC or LIF (first claim = index date) in the IBM® MarketScan® databases from July 2016 to February 2018 were identified. Eligible patients had continuous medical and pharmacy benefits in the 12 months pre- and post-index periods, and no prior use of the index medication. The proportion of days covered (PDC), adherence, non-persistence, discontinuation, and switching were examined over the 12-month post-index period.Results: This study included 6537 CYC and 3235 LIF patients. The adherence rate was 5.9% for CYC and 9.7% for LIF; the median PDC was 0.3 for both cohorts. Overall, 70.8% of CYC and 64.4% of LIF patients discontinued treatment with median days to discontinuation of 89 and 29, respectively. Non-persistence was 7.1% for CYC and 6.8% for LIF (median days to discontinuation: 89 and 105). In addition, 5.0% switched from CYC to LIF, and 9.6% switched from LIF to CYC over the post-index period.Conclusion: Over 60% of DED patients discontinued treatment within 12 months of initiation; the median time to discontinuation was 3 months for CYC and 1 month for LIF. Although this analysis did not capture the reasons why patients discontinued treatment, the results demonstrate there likely exists a significant unmet need amongst DED patients.Keywords: dry eye disease, adherence, persistence, cyclosporine ophthalmic emulsion, lifitegrast ophthalmic solutionWhite DEZhao YOgundele AFulcher NAcs AMoore-Schiltz LKarpecki PMDove Medical Pressarticledry eye diseaseadherencepersistencecyclosporine ophthalmic emulsionlifitegrast ophthalmic solutionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 2285-2292 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	dry eye disease adherence persistence cyclosporine ophthalmic emulsion lifitegrast ophthalmic solution Ophthalmology RE1-994
spellingShingle	dry eye disease adherence persistence cyclosporine ophthalmic emulsion lifitegrast ophthalmic solution Ophthalmology RE1-994 White DE Zhao Y Ogundele A Fulcher N Acs A Moore-Schiltz L Karpecki PM Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
description	Darrell E White,1 Yang Zhao,2 Abayomi Ogundele,2 Nicole Fulcher,3 Annabel Acs,3 Laura Moore-Schiltz,3 Paul M Karpecki4 1Department of Ophthalmology, SkyVision Centers, Westlake, OH 44145, USA; 2Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Princeton, NJ 08540, USA; 3Outcomes Research, IBM Watson Health, Cambridge, MA 02142, USA; 4Corneal Services and Advanced OSD Clinic, University of Pikeville Kentucky College of Optometry, Pikeville, KY 41501, USACorrespondence: Yang ZhaoHealth Economics and Outcomes Research, Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540, USATel +1 609 720 8132Email yang.zhao@sunpharma.comPurpose: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED).Design: Retrospective insurance claims study.Methods: Adult patients with DED and ≥1 prescription claim for CYC or LIF (first claim = index date) in the IBM® MarketScan® databases from July 2016 to February 2018 were identified. Eligible patients had continuous medical and pharmacy benefits in the 12 months pre- and post-index periods, and no prior use of the index medication. The proportion of days covered (PDC), adherence, non-persistence, discontinuation, and switching were examined over the 12-month post-index period.Results: This study included 6537 CYC and 3235 LIF patients. The adherence rate was 5.9% for CYC and 9.7% for LIF; the median PDC was 0.3 for both cohorts. Overall, 70.8% of CYC and 64.4% of LIF patients discontinued treatment with median days to discontinuation of 89 and 29, respectively. Non-persistence was 7.1% for CYC and 6.8% for LIF (median days to discontinuation: 89 and 105). In addition, 5.0% switched from CYC to LIF, and 9.6% switched from LIF to CYC over the post-index period.Conclusion: Over 60% of DED patients discontinued treatment within 12 months of initiation; the median time to discontinuation was 3 months for CYC and 1 month for LIF. Although this analysis did not capture the reasons why patients discontinued treatment, the results demonstrate there likely exists a significant unmet need amongst DED patients.Keywords: dry eye disease, adherence, persistence, cyclosporine ophthalmic emulsion, lifitegrast ophthalmic solution
format	article
author	White DE Zhao Y Ogundele A Fulcher N Acs A Moore-Schiltz L Karpecki PM
author_facet	White DE Zhao Y Ogundele A Fulcher N Acs A Moore-Schiltz L Karpecki PM
author_sort	White DE
title	Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_short	Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_full	Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_fullStr	Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_full_unstemmed	Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_sort	real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/0e24e77112774847966722de87e731be
work_keys_str_mv	AT whitede realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT zhaoy realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT ogundelea realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT fulchern realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT acsa realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT mooreschiltzl realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT karpeckipm realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye
_version_	1718401775934898176

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye

Ejemplares similares